Diabetic ketoacidosis associated with aripiprazole.
BACKGROUND
Atypical antipsychotics have become the mainstay of management of schizophrenia and other psychotic disorders due to low risk of extrapyramidal symptoms. However, postmarketing data has reported atypical antipsychotic agents being associated with hyperglycaemia and diabetic ketoacidosis (DKA). We believe this to be the first published report of hyperglycaemia and DKA with the newest atypical antipsychotic agent, aripiprazole.


METHODS
A 34-year-old African-American female with schizophrenia presented to the emergency department with nausea, vomiting, and malaise for 3-4 days shortly after initiation of aripiprazole therapy. Initial laboratory results revealed significant hyperglycaemia with metabolic acidosis. The patient received treatment for DKA with an intravenous insulin infusion and fluid replacement. Isophane insulin suspension (NPH insulin) was begun immediately following the insulin drip and continued upon discharge from the hospital. Outpatient follow-up information was not available.


CONCLUSIONS
To our knowledge, this is the first case report of aripiprazole associated with hyperglycaemia and DKA. This case is striking in that DKA occurred 4 days following initiation of aripiprazole and the patient had rapid resolution of symptoms and normalization of laboratory values upon discontinuation of aripiprazole. It is important that health-care providers monitor for hyperglycaemia when prescribing atypical antipsychotics including aripiprazole.
Church
C O
CO
Department of Pharmacy Practice, South Western Oklahoma State University College of Pharmacy, Oklahoma City, OK 73101, USA. chelsea.church@swosu.edu
Stevens
D L
DL
Fugate
S E
SE
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D000068180:Aripiprazole; D016883:Diabetic Ketoacidosis / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007328:Insulin / Q000008:administration & dosage; D007336:Insulin, Isophane / Q000008:administration & dosage; D010879:Piperazines / Q000009:adverse effects*; D015363:Quinolones / Q000009:adverse effects*; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D007328:Insulin; D010879:Piperazines; D015363:Quinolones; D007336:Insulin, Isophane; D000068180:Aripiprazole